Literature DB >> 9586871

Behavioral effects of NBQX, a competitive antagonist of the AMPA receptors.

P Filliat1, I Pernot-Marino, D Baubichon, G Lallement.   

Abstract

NBQX, a specific and potent AMPA receptor antagonist has been found to be neuroprotective in various models of ischemia and to have anticonvulsant properties in different models of epilepsy. In this experiment, the neurobehavioral effects of NBQX were studied. In an open field, an important ataxia was emphasized at a dose of 60 mg/kg. In a swimming task, an increase of the escape latencies was noted on the third day at a dose of 40 mg/kg. In a Morris water maze task, doses devoid of effects on locomotion were used (10, 20, and 30 mg/kg). There was no effect on the acquisition of the task at 10 mg/kg and a slight impairment at 20 mg/kg, but the rats did not learn the task at 30 mg/kg. This impairment was reversible, as shown by the increasing performance of this group without treatment. No impairment was noted in the retention phase of the Morris water maze task. The results are discussed relative to the role of the AMPA receptor in memory processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586871     DOI: 10.1016/s0091-3057(97)00518-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.

Authors:  Thomas J Gould; Michael C Lewis
Journal:  Learn Mem       Date:  2005 Jul-Aug       Impact factor: 2.460

2.  Systemic Administration of the AMPA Receptor Antagonist, NBQX, Reduces Alcohol Drinking in Male C57BL/6J, But Not Female C57BL/6J or High-Alcohol-Preferring, Mice.

Authors:  Meredith R Bauer; Daniel P Garcy; Stephen L Boehm
Journal:  Alcohol Clin Exp Res       Date:  2020-10-03       Impact factor: 3.455

Review 3.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

4.  AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).

Authors:  N Galeotti; C Ghelardini; A Pittaluga; A M Pugliese; A Bartolini; D Manetti; M N Romanelli; F Gualtieri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-05       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.